Sushmita Panda

While the LOTIS-5 readout met its primary endpoint of progression-free survival, safety concerns and deaths in the trial could complicate Zynlonta's regulatory path.

With Phase III studies set to begin later this year, AstraZeneca is seeking to position elecoglipron beyond a standalone obesity therapy and as a central component of its broader CVRM franchise.

The diabetes data arrive just weeks after Foundayo's US launch in obesity, with Lilly now seeking to extend the oral GLP-1's reach into a second major indication.

While the company continues to evaluate the future of the VITALIZE trial, the outcome clouds the outlook for one of the more advanced complement-targeting candidates in the indication.

With Phase III already underway, the focus now shifts from biomarker activity to whether del-brax can deliver meaningful functional benefits for FSHD patients.

The companies have delivered positive late-stage data for investigational antifungal olorofim, marking a key development in the program's trajectory.

The voucher sale gives Denali additional financial flexibility as it seeks to advance therapies spanning lysosomal storage disorders and neurodegenerative diseases.

The proposed offering could help advance Definium's pipeline and support a potential launch for DT120.

The financing provides fresh capital for the firm's next stage of growth, including the progression of RQB01 toward clinical development.

Fanregratinib's latest data readout marks an important regulatory milestone for HUTCHMED as it seeks to broaden its portfolio of targeted oncology therapies in China.